Rapid-Fire Roundtable on Melanoma: Focus on Advances in Adjuvant Treatment, Neoadjuvant Treatment, and Management of Metastatic Disease

Target Audience
The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with advanced melanoma.

Program Overview
Treatment for patients with advanced melanoma has been revolutionized through the integration of immune checkpoint inhibitors (CPI) and targeted therapy into management algorithms. With these advances, new challenges have emerged, including identifying the patients who will benefit most from adjuvant and neoadjuvant approaches. In this Rapid-Fire Roundtable educational activity, experts in the field discuss clinical advances pertaining to CPI-based therapy—evaluating patient and tumor characteristics that may inform treatment selection. Faculty will engage in a fast-paced review of the latest data on adjuvant and neoadjuvant regimens as well as emerging options for recurrent melanoma, providing key pearls on immunotherapy to guide clinical decision-making.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Review the latest evidence regarding the use of neoadjuvant treatment for patients with melanoma and the implications for clinical decision-making.
Evaluate patient and tumor characteristics that may help identify patients who may benefit from CPI-based adjuvant therapy based on the latest clinical evidence.
Examine the patient, tumor, and/or treatment characteristics that may help guide clinical decision-making for patients with recurrent melanoma.